STAT+: Perplexing results from Duchenne muscular dystrophy trial raise questions about gene therapies
STAT
OCTOBER 21, 2024
Confounding data from a Pfizer clinical trial has rattled the field of gene therapy for Duchenne muscular dystrophy, raising more questions about the regulatory standard used to approve a treatment from Sarepta Therapeutics, and complicating plans for other companies hoping to develop next-generation products. Scientifically, Pfizer’s gene therapy did what it was supposed to do.
Let's personalize your content